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ABSTRACT 
AN IMMUNOHISTOCHEMICAL STUDY OF BETA-CATI:NIN IN 
HEREDITARY NON-POLYPOSIS COLON CANCER (HNPCC) COLON 
TUMOURS. 
8eta-catenin is normally complexed with adenomatous polyposis coli (APC) 
protein and E-cadherin adhesion molecule, and localized on the cell 
membrane. If APClbeta-catenin is disrupted, beta-catenin transfers into the 
nucleus, where it functions as a transcriptional activator, causing 
unregulated cell proliferation. The localisation of beta-catenin in H NPCC 
adenomas has not been studied but a shift in beta-catenin to the nucleus 
has been previously demonstrated in a range of col 0 recta I cancers, 
including those in HNPCC. The aim of the first part of the study was to 
determine whether there is a beta-catenin shift occurring as an early event 
in HNPCC tumours. Coded sections of tumours were 
immunohistochemically stained with antibody against beta-catenin and 
counterstained in haematoxylin. 14 HNPCC adenomas, 13 HNPCC 
carcinomas, 10 FAP adenomas, 10 FAP carcinomas, 10 sporadic 
adenomas and carcinomas and 10 juvenile polyps -three with dysplasia 
and seven without- were studied. A score was given for loss of membrane 
staining (0-1), presence of cytoplasmic staining (0-2) or nuclear staining (0-
2) and a total out of five obtained. An shift in beta-catenin was 
demonstrated at the adenoma phase in HNPCC. HNPCC ,tumours were 
compared with sporadic tumours and a statistically significant similarity in 
prevalence of beta-catenin shift found in adenomas and carcinomas. The 
early shift in beta-catenin in HNPCC led to the second part of the study 
evaluating the "down-stream" effects of this shift in HNPCC tumours. The 
HNPCC sections were immunohistochemically stained with E-cadherin, c-
myc and cyclin 01. The results showed a positive correlation between E-
cadherin loss, increased cyclin 01 and a shift in beta-catenin. No significant 
change in c-myc or correlation between c-myc and a shift of beta-catenin 
was found. In conclusion the study indicates that disruption of the 
APC/beta-catenin pathway plays a similar role in HNPCC tumours to that in 
sporadic tumours. A notable exeption is the effect on c-myc and further 
study is needed in this regard. 
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CHAPTER 1: INTRODUCTION 
Colon cancer is one of the most common malignancies worldwide, with the incidence in 
developed countries being about 5% of the general population.1,2 Approximately 20% of 
these have a famiJial risk, of which 5-10% have Mendelian inheritance.3 This subset can 
be divided into a number of syndromes, of which hereditary non-polyposis colorectal 
cancer (HNPCC), fammal adenomatous polyposis (F AP) and juvenile polyposis are the 
most frequent and we11-studied. 
The incidence of colon cancer is reported to be lower in African people in South Africa. 
The incidence for Africans is reported as 2 per 100 000, whereas the incidence for white 
males in South Africa is 40 per 100 000.4-6 This is thought to be partially due to 
underreporting in Africans, but a real difference in incidence also exists. This low 
incidence is thought to be related to diet and environment. African Americans have one 
ofthe highest incidences in the world, supporting an environmental influence rather than 
a genetic one.6 The incidence is thus likely to change with progressive Westemisation.7 
1.1 FAMILIAL COLON CANCER SYNDROMES 
1.1.1 FAMILIAL ADENOMA TOUS POLYPOSIS 
Patients with this syndrome present with numerous (lOO's to 1000's) adenomatous 
colonic polyps and untreated have a lifetime risk of colonic cancer approaching 100%.3 
Inheritance is autosomal dominant with approximately 25% having no family history and 
presumably occurring due to new gerrnline mutations.s Gerrnline mutations of the 
adenomatous polyposis coli gene are responsible for this syndrome. The adenomatous 
polyposis coli gene was discovered in 1991 and is situated at chromosome 5q21-22.9 The 
gene is large, comprising 8535 bp spanning 21 exons. Exon 15 accounts for over 75% of 
the coding sequence and most mutations occur at the 5' end of exon 15. Over 300 
gerrnline mutations have been described. Loss or mutation of both APe alleles occurs in 
F AP adenomas as small as 3mm in size. \0 The APe gene product is a large protein with 
multifunctional domains that mediate both oligomerisation and binding to many 
intracellular proteins including beta-catenin, gamma-catenin, glycogen synthase kinase-
3beta (GSK-3bB), axin, tubulin, EBI and hDLG. 11 The majority of APe mutations lead 
to loss of the beta-catenin degradation sites and the associated GSK-3B sites. The mutant 
APe can thus bind but not down-regulate beta-catenin and levels of free cytoplasmic 
beta-catenin increase. \0 Studies of sporadic tumours have demonstrated that the APe 
gene is not only important in F AP, but responsible for initiation of the majority (>80%) 
of sporadic cases of colorectal cancer. I 
1.1.2 JUVENILE POLYPOSIS 
Juvenile polyps are characterized histologically by dilated crypts in a loosely packed 
oedematous stroma with no glandular dysplasia. The majority of polyps are colorectal. 
They may be sporadic or occur as part of familial juvenile polyposis. Juvenile polyposis 
is an autosomal dominantly inherited syndrome characterized by multiple juvenile polyps 
of the gastrointestine. 
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The patients also have an increased risk of tumours of the stomach, duodenum, biliary 
tree and pancreas. Two thirds of patients present in the first two decades of life and 
untreated about 60% will have colorectal cancer by 60 years of age.12 Clinically the 
syndrome is characterized by greater than five juvenile polyps in the colorecturn, juvenile 
polyps throughout the gastrointestinal tract or a family history with any number of 
juvenile pOlypS.13 There are two possibilities for the development of cancer in these 
patients. These are from an adenoma arising de nova, or via adenomatous change in' a 
juvenile polyp. Pure adenomas have been found to be rare and dysplastic change has been 
found in about 10% of classic juvenile polyps. Atypical juvenile polyps are multilobated 
and often adopt a villous or papillary configuration. Dysplasia of varying severity is 
found in 50% of these lesions. The finding of these mixed juvenile polyp/adenomas 
favours the later mode of carcinogenesis. 13 Juvenile polyposis appears to be a genetically 
heterogeneous syndrome, but mutations in the Smad4 gene on chromosome 18q21.1 have 
been found in some families. The frequency of this mutation has been reported as 
anything from 20 to >50% of patients. Smad4 is an important mediator in the 
transforming growth factor-beta pathway, and thus has a role in regulating the 
transcription of genes involved in cell cycle and transcriptional regulation. The genes 
regulated include the cyclin dependent kinase inhibitors pI6 and p2I, cyclin DI and 
TGF- B itself.14 
3 
Figure 1.1 :Smad 2 and 3 are phosphorylated by activated TGF-B. They bind with each 
other and with Smad4. The complex then transfers into the nucleus were it regulates the 
transciption of genes. 15 
1.1.3 HEREDITARY NON-POL YPOSIS COLORECTAL CANCER 
Hereditary non-polyposis colorectal cancer is the most common hereditary colon cancer 
syndrome, with the quoted incidence varying between 1 and 10%.16,17 There is no single 
pathognomonic feature that characterises this disorder. It can be recognized clinically by 
a combination of features, described initially by Lynch. 18 These criteria were 
standardised by the International Collaborative Group on HNPCC in 1990, to provide 
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uniformity in collaborative studies. The criteria (called Amsterdam Criteria 1) were since 
modified, to include extra-colonic cancers, and called the Amsterdam Criteria II, namely: 
There should be at least three relatives with an HNPCC-associated cancer: colorectal 
cancer (CRC), or cancer of the endometrium, small bowel, ureter or renal pelvis. 
• One patient should be a first degree relative of the other two. 
• At least two successive generations should be affected. 
• At least one tumour should be diagnosed before age 50 years. 
• Familial adenomatous polyposis should be excluded in the CRC easels, if any. 
• Tumours should be verified by histopathological examination .15 
Diagnosis ofHNPCC can be made by fulfillment of these criteria or by genetic testing for 
germ line DNA mismatch repair mutations. 3 
The colonic tumours in HNPCC are frequently of the right colon and may be multiple. 
Adenomas are less frequently seen and occur in a smaller number compared to those in 
FAP, hence the name non-polyposis. The relatively small numbers of adenomas is 
explained by a rapid accumulation of genetic mutations and thus rapid progression from 
normal epithelium through adenoma to carcinoma. 8 
The genetic defect in HNPCC is an abnormality in DNA repair. The mode of inheritance 
is autosomal dominant, with a 70-80% penetrance.16 Germline mutations in hMLH1, 
hMSH2, hMSH6, hPMSl and hPMS2 have been identified, with hMLHl and hMSH2 
5 
accounting for more than 80%.16,8,3,11 Studies in yeasts show that MSH2 complexes with 
either MSH6 to recognize single base pair mismatches, or with MSH3 to recognize larger 
2 to 4-base pair deletions or insertions. The MLHI and PMS2 gene products then excise 
the mismatched nucleotides from the newly synthesized strand. Defects in the mismatch 
repair (MMR) system thus result in many DNA replication errors. These errors are 
usually detected in simple repetitive sequences, the so-called microsatellites. 
Microsatellites are present in coding and non-coding DNA throughout the genome. 
Defects in MMR results in micro satellite instability in which the length of these normally 
stable repeats varies considerably.19 This microsatellite instability can be detected in the 
vast majority of HNPCC cancers. 20 
HNPCC IN THE WESTERN CAPE 
294 families composed of 1079 individuals have been identified in the North Western 
Cape area. 291 of these families have had mutational screening and those who are 
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A number of genes have been identified as targets for wnt signaling. Cyclin D 1 is a well 
known oncogene which stimulates cell proliferation by allowing progression through G 1 
of the cell cycle. When a cell receives growth promoting signals it synthesizes cyclin D1. 
This cyclin DI binds to cyclin dependant kinase (CDK) 4 and then 6 in early GI of the 
cell cycle. The CDK 4 and 6 then phosphorylate Retinoblastoma protein (Rb). In the 
unphosphorylated state Rb is bound to E2F transcription factors and inactivates them. 
Phosphorylation of Rb releases E2F which is then responsible for the synthesis of factors 
necessary for progression through the S phase of the cell cycle.35 Cyclin Dl gene 
contains a binding site for TCFILEF. The binding of TCFILEF stimulates cyclin DI 
synthesis which promotes cell proliferation. Increased beta-catenin has been shown to be 
associated with an increase in cyclin D 1 in colon cancer cell lines.36 This is thus one 
mechanism whereby wnt pathway activation and beta-catenin accumulation is thought to 
lead to uncontrolled cell proliferation. An increase in nuclear cyclin DI has been 
demonstrated at the adenoma stage in FAP and in 30% of un selected colorectal adenomas 
and carcinomas.37,28 
C-myc is another oncogene identified as a target for wnt signaling. C-myc proto-oncogene 
is expressed in virtually all cells. When a cell receives a growth stimulus the levels of c-
myc increase rapidly and then decline to a basal level. After translation c-myc is 
transported to the nucleus, binds to DNA and acts as a transcriptional activator, 
promoting cell proliferation.39 As early as 1989 deregulation of c-myc in colonic cancers 
was found to be linked to allele loss on chromosome 5q.40 This is now known to be the 
site of APC gene loss. The link between APC and c-myc has been reported to be beta-
11 
catenin, which regulates transcription of c-myc via the TCF transcription factor.41 
Gamma-catenin (plakoglobin), a protein with analogous structure and function to beta-
catenin, is also regulated by binding to APC.42 Kollings et al. showed that gamma-
catenin activation of the TCF transcription factor leads to an increase in c-myc 
expression. This function was independent of beta-catenin, which they found to have no 
effect on c-myc expression.43 Gamma-catenin expression is increased in about 85% of 
sporadic colon cancers.44 
Numerous studies in the late eighties and early nineties showed an increase in c-myc 
RNA and protein in colonic carcinomas using Western blotting, Northern blotting and 
immunohistochemical staining.45,46,47,48 Elevated levels of c-myc have also been 
demonstrated at the adenoma stage in FAP.37 A study comparing c-myc expression with 
tumour grade showed varied staining results. Increased nuclear staining was seen in well 
differentiated lesions and decreased nuclear uptake with cytoplasmic staining in poorly 
differentiated tumours.49 Predominantly cytoplasmic staining was also found by Imaseki 
et aI., but this was irrespective of tumour grade.47 It is not known whether cytoplasmic 
c-myc reflects only inability to reach the nucleus, or whether it has a specific role in the 
cytoplasm.49 Wang et al. challenged this elevated c-myc in their recent studies. Using 
immunohistochemistry and PCR they demonstrated that while c-myc m-RNA was 
increased in 2/3 of tumours, c-myc nuclear protein expression as detected by 
immunohistochemistry, was not increased. This was substantiated by Western blotting, 
which also showed an unaltered or decreased c-myc level. 50 
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Aside from disordered cell proliferation, tumour invasion also requires digestion of the 
basement membrane and extra-cellular matrix. The matrix metalloproteinases are a 
family of enzymes responsible for extracellular matrix and collagen digestion. Matrix 
metalloproteinase 7 (MMP7) is, unlike the other metalloproteinases, produced 
exclusively by tumour cells.54 MMP7 is overexpressed in 80% of unselected colorectal 
carcinomas. MMP7 has also been demonstrated to playa role in adenoma development as 
the inhibition ofMMP7 suppresses adenoma formation. The MMP7 gene has two binding 
sites for TCF and is activated by beta-cateninlTCF. ss Beta-catenin increase and shift to 
the nucleus has been associated with increased MMP7 in immunohistochemical study of 
human sporadic colon cancers?1,S4 The increased levels were found to be present at the 
adenoma phase. 
Laminin-gamma-2 is an invasion marker which is overexpressed in the invasive front of 
colorectal carcinomas. Laminin is a component of the basement membrane. It is cleaved 
by the matrix-metalloproteinases and the gamma-2 chain activates cell migration. Beta-
catenin and laminin-gamma-2 have been shown to be overexpressed at the invasive 
tumour front. Beta-catenin activates laminin-gamma-2 and thus enhances the ability of 
tumour cells to invade. S6 
Another important factor in tumour progression is angiogenesis. Vascular endothelial 
growth factor (VEGF) has been found to be important in most tumours. It has also been 
shown to be increased at the colon adenoma stage. The regulators of VEGF are different 
in different tissues . .In colon cancer cell line experiments VEGF is regulated by K-ras and 
beta-cateninlwnt signaling. S7 
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Beta-catenin is also implicated in colonic cell differentiation. Cell line experiments have 
shown that down-regulation of beta-cateninffCF occurs with colonic cell 
differentiation. 58 This function is thought to be mediated indirectly by down-regulation 
of transcription factors whose nonnal role is to repress the expression of genes associated 
with the onset of differentiation. Cdx-l, encoding a homeobox factor,Id2 (inhibitor of 
differentiation-2) and ENCl (ectodennal neurocortex 1) have been identified. Homeobox 
genes are genes containing a 180 nucleotide motif, the homeobox, which is conserved 
between species and in vertebrates is implicated in the patterning of limbs and 
vertebrae. 21,58,59 
The combination of all these factors makes beta-catenin a potent oncogene. The loss of 
membranous beta-catenin and accumulation of nuclear beta-catenin contributes to the 
ability of tumour cells to proliferate, survive, dedifferentiate and invade. 
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1.3 COLORECTAL CANCER CARCINOGENESIS 
The multistep process of carcinogenesis, with mUltiple genetic mutations occurring in 
sequence, is well recognized and described in well known pathology texts.35,60 Colon 
cancer has long been recognised to result from progression of normal epithelium through 
gradually more dysplastic adenomas to carcinoma. The study of these preneoplastic 
lesions, particularly in FAP, has done much to contribute to the understanding of 
carcinogenesis in general. 
The well-known classic, or "gatekeeper", pathway of colorectal carcinogenesis was 
defined mainly through study of F AP adenomas and carcinomas. In F AP a germline 
mutation in APe gene, followed by somatic mutation of the wild type allele, results in the 
development of numerous adenomas. The somatic mutation is thus the rate limiting step 
in this process and APe is known as a "gatekeeper" gene.9 "Gatekeeper" genes are 
responsible for maintaining a constant cell number in renewing cell populations. 
Mutation of other genes, in the presence of a normal gatekeeper gene, does not result in 
adenoma development. Evidence supporting this role for APe is that APe mutations are 
found in the earliest dysplastic lesions (aberrant crypt foci) and mutation of other genes, 
such as p53, do not result in adenomas in the absence of an APe mutation. More than 
80% of sporadic adenomas and carcinomas have been demonstrated to have a somatic 
APe mutation.9 The pathway of carcinogenesis is thus thought to follow roughly the 
same pattern of mutations in all these lesions.2o The initial loss of APe is followed by 
loss of other tumour suppressor genes, namely K-ras at the adenoma stage, TP53 on 
chromosome 17 and deletions on chromosome 18q at transition to malignancy.Il,61 The 
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inactivation of the second copy of these genes is usually by non-dysjWlctional loss 
leading to loss of heterozygosity. This loss of heterozygosity is correlated with gross 
chromosomal changes and these tumours are invariably aneuploid.10 
Not all adenomas have a polypoid configuration. Flat adenomas are described and may be 
early (not yet polypoid) lesions or represent horizontal spread of proliferating tubules. 
The flat adenomas have been noted to often lack k-ras mutations.62 
A second "mutator" pathway has more recently been elucidated through study of HNPCC 
cancers.20 In HNPCC an inherited mutation of a mismatch repair gene, with somatic loss 
of the second copy, leads to failure to repair errors that occur during DNA replication. 
This results in mutations of single nucleotides and alterations in simple repetitive 
microsatellite sequences. Microsatellites are tandem repeats of simple sequences that 
occur abWldantly and randomly throughout the genetic sequence. They consist of 10-50 
copies of 1-6bp motifs that can occur as perfect tandem repeats, imperfect (interrupted) 
repeats or as a combination of the two types. The repeats are prone to replication errors 
during DNA replication, but these are normally repaired by DNA mismatch repair 
proteins. The length of a repeat is thus normally transmitted Wlaltered through mitosis 
and meiosis. Novel alterations of these sequences have been demonstrated in tumours.63 
These alterations in the microsatellites, termed microsatellite instability (MSI), are the 
characteristic phenotype of HNPCC and are detected in the majority of these tumours. 11,20 
Thus there is DNA instability rather than the chromosomal instability seen in the classic 
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pathway. Once the initial mismatch repair defect is present the lesions progress rapidly 
to carcinomas, because of the increased mutation rate. 
The presence of MSI, in sporadic and HNPCC tumours, has been noted by various groups 
since 1993. A National Cancer Group Workshop in America met in 1997 to establish 
acceptable criteria for defining a MSI tumour. Five markers, including two 
mononucleotide and three dinucleotide markers, were selected. MSI-high (MSI-H) 
tumours were defined as having instability in two or more markers, while MSI-low (MSI-
L) have instability in one marker. Microsatellite stable (MSS) tumours are those showing 
no instability using these five markers.64 Subsequent studies have usually included these 
markers, although additional markers have often been added.65 Using these criteria 10-
15% of all colorectal cancers are MSI-H.64 
The vast majority of sporadic MSI-H tumours have been shown to have hypermethylation 
of the MLHI promoter, suggesting that this is the primary mechanism underlying MSI-H 
in sporadic tumours. 11,66 Both hypermethylation and hypomethylation of DNA have been 
linked to colonic cancer. Methylation occurs at CpG sites. CGIs are short sequences rich 
in CpG dinucleotide found in the 5' region of about half of all human genes. Methylation 
of cystine within 5' CGIs is associated with loss of gene expression.67,68 Physiological 
methylation is seen in conditions such as X chromosome inactivation. Aberrant 
methylation of CGIs is associated with transcriptional inactivation of tumour-suppressor 
genes in neoplasms, including colorectal cancer. 69 Two distinct types of 
hypermethylation are described in cancer. Type A (A for aging-specific) and Type C (C 
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for cancer-specific). Type A methylation of genes occurs in an aging-related manner in 
normal colonic epithelium, and hypermethylation of these genes occurs at a high 
frequency in colorectal cancer. In contrast type C methylation is never seen in normal 
epithelium and is relatively infrequent in cancer epithelium. A minority of tumours 
display high levels of type C methylation. MLHI is methylated in about 50 % of these 
tumours.67 These account for the majority of MSI-H sporadic colorectal cancers. II 
Morphologic features noted in MSI-H cancers are predominance of right sided lesions, 
poor differentiation, mucinous differentiation, intra-epithelial and Crohn's-like 
lymphocytic infiltration, reduced invasiveness, improved prognosis, female 
preponderance and multiplicity.7o With the exception of lymphocytic infiltration these 
features have been found to be more pronounced in sporadic MSI-H cancers than in 
HNPCC.71 
The discovery of this proposed second "mutator" pathway of carcinogenesis led to 
numerous studies attempting to establish whether DNA instability leads to accumulation 
of genetic alterations in oncogenes and tumour suppressor genes similar to those found in 
the classic pathway. Most early studies did not make the distinction between sporadic 
MSI-H tumours and HNPCC tumours.71 A number of differences emerged between 
Microsatellite stable (MSS) and Microsatellite instability-high (MSI-H) tumours. 
Mutations involving TGF-B type 2 receptor gene are characteristic of MSI tumours. This 
mutation causes the cell to express an abnormal TGF-B receptor on its surface, and 
thereby fail to bind TGF-B, which has a potent tumour suppressor activity. Mutations of 
TGF-B have not been detected in MSS tumours. 16,72 Mutations of IGF-2R and bax have 
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also been found at increased frequency in MSI-H cancers. Numerous studies have shown 
a decreased incidence of APe, p53 and k-ras mutations in sporadic MSI-H 
cancers?0,59,73,19,71,74 A study by Shitoh et al. on Japanese sporadic colorectal cancers 
disagreed with this and found a decreased K-ras mutation rate, but no difference in APe 
and p53 mutation rate between MSI-H and MSS cancers.75 Huang et al. also found a 
high incidence of APe mutations (50%) in MSI-H cancers.76 This apparent disparity is 
explained by Jass by dividing MSI-H cancers into those from patients with HNPCC and 
those occurring in a sporadic setting.71 The cases in the study of Shitoh et al. were 
known to include HNPCC caseS.75 The Huang et al. study only included six MSI-H 
cancers and Jass et al. argues that HNPCC cases may have been unknowingly 
included. 76,7 1 Recent studies lend support to this suggestion as studies including only 
HNPCC cancers have found a 20%71,77 to 50010 mutation rate in APC.78 
Since the main function of APC appears to be regulating beta-cate~ many groups have 
looked for beta-catenin mutations in tumours with preserved APC. Experiments on 
carcinogen-induced rat colon cancers have demonstrated a high incidence of beta-catenin 
mutation, especially in exon 3, in tumours with no APe mutation.79-82 This was thus 
proposed to be a different method of disruption of the APClbeta-catenin complex, and 
ultimate activation of wnt signaling, with its downstream effects. Morin et al. showed 
that mutations rendering beta-catenin insensitive to APC-induced phosphorylation had 
the same effect as APe mutations?4 Studies of unselected colon cancers have shown 
beta-catenin mutations in 13% - 50% of cancers without APe mutation. 83-85 Salashor et 
al. looked for beta-catenin mutations in unselected MSI-H cancers and found none. 20 
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Loving et al. found no mutations in sporadic MSI-H cancers.74 This is in contrast to 
Rowan et al. who found a high frequency of beta-catenin in MSI-H without APe 
mutations (417). It is not known what percentage of these tumours was from HNPCC 
patients. The sample in the study of Salashor et al. was from unselected cases while 
Rowan et al. used cell lines. Miyaki et al. studied HNPCC tumours and found APe 
mutations in 20% and beta-catenin mutations in 50%.(Miyaki Met al. 1999) Review of 
this data lends weight to the suggestion that HNPCC tumours have a different genetic 
profile to MSI-H tumours. The histogenesis also appears to be different. While they are 
not frequent in comparison to adenomas in F AP, adenomas are seen in HNPCC. 
Carcinomas can also be seen arising in these adenomas.71 In contrast, sporadic MSI-H 
adenomas are rarely seen and these tumours appear to arise through serrated polyps.87-90 
Serrated polyps include hyperplastic polyps, mixed polyps and serrated adenomas. 
Serrated adenomas are polyps with dysplasia and crypt infolding. 71 
The current evidence, published predominantly by Jass et al, is thus that HNPCC cancers 
have a similar rate of disruption of the wnt pathway as sporadic lesions, but that sporadic 
MSI tumours have little evidence of wnt disruption. While it is usually assumed that wnt 
disruption is an early "gatekeeper" event, very few studies have examined APe and beta-
catenin mutation or beta-catenin shift to the nucleus in HNPCC adenomas. Akiyama et 
al. studied 14 HNPCC adenomas and found APe mutations in 50% and beta-catenin 
mutations in 14% of those without APe mutations.77 
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CHAPTER 2: BETA-CATENIN STUDY 
The first part of the study aimed to confirm the shift in beta-catenin previously reported 
in F AP, juvenile and sporadic lesions and to determine if this complex is playing a 
similar role in the early development of HNPCC lesions. The hypothesis was that beta-
catenin shift to the nucleus would occur in HNPCC adenomas at an equal frequency to 
that occurring in sporadic adenomas. 
2.1 AIM 
To examine the expression and distribution of beta-catenin in colorectal adenomas and 
carcinomas in order to 
1) confirm the findings ofbeta-catenin staining in FAP, juvenile and sporadic adenomas 
and carcinoma 
2) determine ifbeta-catenin staining is altered in HNPCC 
3) determine ifbeta-catenin alteration is an early or late event in HNPCC 
2.2 MATERIALS AND METHOD 
A thesis proposal was submitted for approval to the Groote Schuur HospitalfUniversity of 
Cape Town Ethics Committee and ethical approval was obtained. 
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2.2.1 MATERIALS 
Ten cases each of F AP and sporadic adenomas and carcinomas, and 10 polyps from 
patients with juvenile polyposis were included in the study. Only one adenoma and/or 
carcinoma was used from anyone patient. For each case a single block was chosen. 
Where available the section included both tumour and adjacent normal epithelium. 
Seven F AP cancers from the Anatomical Pathology Division of Groote Schuur Hospital 
were included and three additional cases were obtained from the Anatomical Pathology 
Department of Tygerberg Hospital. The patient ages ranged from 15 to 78 years (mean 
45yrs). Ten adenomas were randomly chosen from ten different FAP patients, who had 
previously undergone polypectomy or colonic resections, at Groote Schuur Hospital. The 
age range was 29 to 60 years (mean 25yrs). The ten polyps from patients most recently 
diagnosed with juvenile polyposis, available at the Anatomical Pathology archives at 
Groote Schuur Hospital, were chosen. All HNPCC cases available at the Anatomical 
Pathology Division of Groote Schuur Hospital were used in this study. This included 14 
adenomas and 13 carcinomas. The ages of the patients with adenomas ranged from 29 to 
73 years (mean 36yrs), and carcinomas from 24 to 73 years (mean 39yrs). All the 
carcinomas were sited in the right side of the colon. Ten sporadic adenomas and ten 
sporadic carcinomas were selected from sequential cases reported by the investigator and 
two colleagues, in the period of 2000 to 2002. The age range of patients with adenomas 
ranged from 31 to 78 years (mean 65yrs). The age range of patients with carcinomas was 
from 52 to 78 years (mean 64yrs). Eight of the ten carcinomas originated from the left 
side of the colon. 
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Figure 2.2: Typical (a) adcnomatolL~ polyp and (b) invllli;"e cuncer occurring in FAI' . 
I-INPCC and 5pOradic sellings. 
2.2.2 METHOD: Beta-catenin immuoohistocbemistry 
The chosen method for 115Sl"SSing protdn upre!:!lliation LD this stud) WlIS through 
immunohistochemistry. This mt.'thod has the oovunlllb<e of giving oot only an estimate of 
the qWlnlil)' <If a protein in II cell bUI ,,1..0 the subcc:llul", lo.:alion of !he pmtei'L n,i~ 
kno ..... ledge is vital with bcUl~nin lIS it is fulfilliug differenlrolCll at different sites. The 
sUlins can also be performed on fomalin-fixed, paraffin WIIX-embedded tiS.~I1C. v.hich 
makes study of archival material possible. A disadvantage is that assessment of protein 
qWlllti ty is based on II visual evaJu.ltion of !ilaining inlll1lsily and is IhllS subjective. 
Pilot Study 
In 2001 a pilot study was performed in the immunohistochemical Illborulory 01 UK: 
Division of AllIIwmicai Pathology. Groote Schuur Ilospital OIl seven FAT' carcinomas. 10 
assess beta-calcnin swining. FAP c3reiDOfllas .... 'ere chosen as thtsc lesions ha\1: been 
well described 10 I1lIve a shift in bcta-cmcnin from thl- cdl membrane 10 lhe nocleus in all 
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cases.93 The cases were all the FAP cancers currently available in the archives of the 
Anatomical Pathology Division at Groote Schuur Hospital. A section showing both 
invasive tumour and nonnal epithelium was chosen for each case. 
Immunohistochemical protocol 
2-3micrometer paraffin wax-embedded sections were floated onto APES-coated slides 
and incubated overnight in a 60°C incubator. Sections were dewaxed in xylene, 
rehydrated in graded ethanols and washed in water. The sections were blocked for 
endogenous peroxidase in a 3% H202 water solution for 5 minutes. After washing in 
water, heat-mediated antigen retrieval with a citrate buffer and pressure-cooking was 
perfonned at pH6. Sections were rinsed in phosphate buffered saline (PBS) pH7.6. Non-
specific binding was blocked using a 5% goat serum solution at room temperature for 10 
minutes (Dako X0907). The goat serum was drained off and the sections were incubated 
with the beta-catenin antibody (NCL-beta-catenin;Novocastra,UK) at a dilution of 1:100 
for 2hrs at room temperature. Sections were well washed in PBS and then treated with 
goat anti-mouse immunoglobulins labeled with horseradish peroxidase (Envision:Dako 
04001) at room temperature for 30 minutes. Sections were washed in PBS and positivity 
developed by applying 3.3'-diaminobenzidine (Dako K3466) at room temperature for 5-
10 minutes. Sections were washed well in water and counter-stained in haemotoxylin, 
followed by dehydration using graded ethanols and xylene before mounting with entallan. 
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The protocol was established after trying the commercially recommended protocol and 
making adjustments. Sections of normal colonic epithelium and colon cancers were 
stained at various dilutions for different lengths of incubation. The results in normal 
epithelium were then compared with that reported in previous studies and the dilution and 
length of incubation selected to produce similar results. 
Normal epithelium: Staining was isolated to the cell membrane. No cytoplasmic or 
nuclear staining was present. This is in accordance with previous studies.21 ,92-94 Loss of 
membrane staining and positive staining in the cytoplasm and nucleus were seen in some 
adenomas and carcinomas. 
Immunohistochemical scoring 
Staining was evaluated according to the presence of membranous, cytoplasmic and 
nuclear staining. The scoring system described by Jass et al. was used in this study.95 
Membrane staining Cytoplasmic staining Nuclear staining 
o =no loss 0= absent o = absent 
1 = loss 1 = weak 1 = weak 
2 = strong 2 = strong 
The three scores were then added to give a total out of five, with four or five considered a 
positive result. 
Beta-catenin staining has been shown to be greater at the invasive front of tumours.95 If 
this area was available it was evaluated. In the case of biopsies the highest scoring area of 
the available tissue was scored. 
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The tumours were coded and scored by the investigator, who was blinded to the origin of 
each tumour. A random sample of the tumours was then scored by a second pathologist. 
The results were statistically analysed using the chi-squared and Mann-Whitney tests. 
2.3 RESULTS 
All of the F AP adenomas had some shift in beta-catenin staining. 7/10 cases had a score 
of four or five (Table 2.1). All of the FAP carcinomas had complete shift with a score of 
five. (Table 2.2) 
Table 2.1: Beta-catenin score in F AP adenomas 
Code Membrane Cytoplasm Nucleus Total 
FA 1 1 1 2 4 
FA2 1 2 2 5 
FA3 1 2 2 5 
FA4 1 'I 1 3 
FA5 0 1 0 1 
FA6 0 1 1 2 
FA7 1 2 2 5 
FA8 0 2 2 4 
FAg 1 2 2 5 
FA 10 1 2 2 5 
Beta-catenin staining scored according to the presence of membranous, cytoplasmic and 
nuclear staining. Membrane staining scored 0 if present and 1 if absent. Cytoplasmic and 
nuclear staining scored 0 if absent, 1 if weak and 2 if strong. The three scores are then 
added to give a total out of five, with four or five considered a positive result. 
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2.4 DISCUSSION 
The majority of sporadic colorectal cancers are known to occur via the classic pathway of 
carcinogenesis with progression from normal epithelium, via adenomas, to carcinomas.61 
Mutation of the APC gene plays a crucial "gatekeeper" role in these tumours. Mutation of 
the APC gene leads to decreased posphorylation and degradation of beta-catenin, and a 
shift of beta-catenin from the cell membrane to the nucleus. Beta-catenin then binds to 
TCF transcription factors and leads to increased cell proliferation and decreased 
apoptosis?3 
Tumours occurring in the setting of HNPCC, and a small subset of sporadic tumours, 
have loss of DNA mismatch repair genes as the initiating event and follow the so-called 
"mutator" phenotype. The role of the APClbeta-catenin complex in these lesions is not as 
well defined. 
The results of this study show a shift in beta-catenin in 7/10 F AP adenomas and 10/1 0 of 
the F AP carcinomas. Inomata et al. showed beta-catenin shift in all their F AP adenomas 
and carcinomas.93 The finding of beta-catenin shift in all the cases in this study is in 
accordance with this result. They did not attempt to score cases beyond positive or 
negative for shift. 
In the juvenile polyposis cases beta-catenin shift was found only in the polyps with 
dysplasia. The remainder of the lesion had membranous beta-catenin staining. A similar 
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fmding of beta catenin shift in polyps of juvenile polyposis has been previously 
reported.96 The finding of focal beta-catenin nuclear staining in those lesions with 
dysplasia indicates that wnt pathway disruption is probably implicated in the 
development of carcinomas in these lesions. 
A shift in beta-catenin staining to the nucleus was seen in five out of ten sporadic 
adenomas. Previous immunohistochemical studies of beta-catenin in sporadic adenomas 
have shown very varied results. Inomata et al. found no nuclear staining, Hao et al. found 
nuclear staining in 50% of adenomas, Valizadeh et al. in 65% and Iwamoto et al. in 
100%.93,92,25,94 In carcinomas Hugh et al. showed beta-catenin shift in 75% with nuclear 
staining in 50%.97 Hao et al. showed nuclear staining in 78.8%.92 Wang et al. in 83% 
and Iwamoto et al. in 100%.50,94 The scoring system for each of these studies was 
different. Hao et al. viewed nuclear staining in >5% of nuclei as positive and Iwamoto 
required nuclear staining in > 1 0% of tumour cells. 92,94 Wang reported any nuclear 
staining as positive and >50% staining as diffuse. 50 Hugh et al. divided beta-catenin 
score into negative (no staining), focal (less than 75%) and diffuse (>75%).97 This 
variability in scoring highlights the difficulty experienced when attempting to evaluate 
and compare the results of different immunohistochemistry studies. 
The tumours in these above mentioned studies were not stratified according to 
micro satellite instability. Microsatellite evaluation was not available for the current study. 
Sporadic lesions should ideally have been stratified into MSI-H and MSS lesions to allow 
comparison between these two groups and the HNPCC tumours. An attempt was made to 
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do this by immunohistochemically testing for loss of MLHI, MSH2 and MSH6. This 
staining was done using the method previously devised by the investigators research 
consortium.91 All the cases chosen had preserved mismatch repair staining and are thus 
unlikely to be from unsuspected HNPCC or sporadic MSI-H cases. 
Nuclear beta-catenin staining was demonstrated in seven of 14 HNPCC adenomas and 11 
of 13 HNPCC carcinomas. Despite the small sample size, these results show statistically 
significant similarity to the results for the sporadic adenomas and carcinomas, thus 
supporting the hypothesis. 
Mutational analysis of HNPCC cancers has shown that the combination of beta-catenin 
or APC mutation occurs with approximately equal frequency in these tumours as in 
sporadic cancer. Immunohistochemical localization of beta-catenin can be expected to 
reflect this. This is supported by this study. The study also demonstrates that the situation 
in the South African cases is similar to that found in European and Japanese studies. The 
immunohistochemical demonstration of a beta-catenin shift at the adenoma stage is, to 
the investigator's knowledge, a new finding. A single Japanese study showed beta-
catenin and APC mutations to be present in a percentage of these adenomas. The study 
was based on 14 adenomas from Japanese patients with HNPcc. 78 The finding of beta-
catenin shift in the HNPCC tumours led to the second part of the study looking at the 
"down stream" effects of this shift. 
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CHAPTER 3: E-CADHERIN, CYCLIN Dl AND C-MYC STUDY 
The hypothesis was that the E-cadherin, cyelin D 1 and c-myc staining in HNPCC 
adenomas and carcinomas would be the same as that reported in sporadic cases. A further 
hypothesis was that the decrease in E-cadherin and increase in cyclin D 1 and c-myc 
would be positively correlated with nuclear beta-catenin staining. 
3.1 AIM 
To examine the expression and distribution of E-cadherin, cyelin DI and c-myc in 
HNPCC adenomas and carcinomas to 
1) determine if E-cadherin membranous expression is decreased in HNPCC 
2) determine if cyelin D 1 and c-myc nuelear expression is increased in HNPCC 
3) determine the relationship between beta-catenin distribution and the expression of E-
cadherin, cyclin D 1 and c-myc. 
3.2 MATERIALS AND METHOD 
The same HNPCC adenoma and carcinoma blocks used in the beta-catenin study were 
used. Immunohistochemical staining for E-cadherin, cyelin D 1 and c-myc was performed 
using the same immunohistochemistry protocol that was used in the beta-catenin study, 
with the following antibody dilutions and incubation times: 
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AG retrieval Ab dilution Time Buffer 
E-cadherin( code081223)Zymed 
C-myc (Clone 9E10)DAKO, USA 
pH6 
pH8 







Background staining occurred with the cyelin D1 (codeM7155;DAKO,Denmark) and c-
myc (Clone 9E10;DAKO, USA) antibodies. Blocking for endogenous peroxidase and 
treatment with goat serum improved, but did not totally remove, this staining. The 
staining did not however obscure the morphology of mucosal staining. 
3.2.1 E-CADHERIN 
Normal epitheliwn: baso-lateraI membrane staining was present. 
Loss of membrane staining was evaluated and a score of 1 awarded for <30% loss (focal) 
and 2 for >30% loss (diffuse). This scoring system was adapted from that used by 
Gagliardi et al.31 
The coded sections were scored by the investigator and a second pathologist 
The E-cadherin results were correlated with the beta-catenin results. 
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3.2.2 CYCLIN DI 
Weak membranous and cytoplasmic staining was present in the nonnal epithelium. No 
nuclear staining was observed. 
Staining could not be perfonned on one adenoma as the tissue had cut away. Nuclear 
staining was assessed and a score of 1 awarded for positive staining in <30% of tumour 
nuclei and 2 for staining in> 30010 of tumour nuclei. 
The sections were scored by the investigator and a second pathologist. 
The cyclin DI results were correlated with the beta-catenin results. 
3.2.3 C-MYC 
Strong nuclear staining was seen in the crypts and surface epithelium in the nonnal 
mucosa. Weak cytoplasmic staining was also observed. The staining was unifonn 
throughout to the length of the epithelium. Occasional inflammatory cells in the stroma 
also stained positive. The nuclear and cytoplasmic staining in the carcinomas was 
compared to the nonnal epithelium and reported as weaker, the same or stronger staining. 
The adenomas were not evaluated as the tissue had cut away in 5114 and only two polyps 
had adjacent nonnal epithelium for comparison. Attempts were made to quantify the 
difference in staining in tenns of percentages, but this was found to yield too much intra-
observer and inter-observer variation. Good intra-observer and inter-observer 
reproducibility was found using the simple more, less or the same staining system. 
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dilT~rencl.' in nucl<'ar SWining com~ 10 I1lI.' wJJIICl'1I1 nolmlal rnucoSli and si:>. lumnun; 
had decrellSl.-d nuel"'''' stalnin\l. locre-J!iCd c)'wplasmic 'ilUining was seen in the IUmoun; 
in~ luding the 11m.'l! Ca3C$ wi th incre-.. scd nuclear ~11l1Ilillll . 
No n'1ationshi p bel\\ ern bcta-CBlcrUll and nuclcllT c·mye staining could I)C dcmonsTfllk-d 
Nuclear siaining showed no n: lmionship 10 IUI\10ur grade 
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Figur.: J.J: 3) c_my<: expression in IlOmml muCOSll b) c-myc In IlNI'CC carcinoma of 
same palient. 
Table 3.2: Nuclear llJ1d C~!OplilSmic c-myc ~xpressioll in an IINf>C(" carcinoma compared 
10 the adjacent nomml epithelium 
)A IlISCUSSION 
b~ldcncc ofbcta-calcnin shill to lhe nllClcus in IINI'CC wmours led \0 (lie SI:<:Ooo pan of 
th.: shidy looking at the dO"TI-sl!'eam di«1S of lhi~ shift. Smdks In sPQrdrlic carcinomas 
hu\'c Imked bela-calcninfwnl \0 upreguJolioll of cyclin 01 and c-myc. Loss of 
mcmbrooous bcla-calt!nin has also been linked 10 II decfCase in E-cadherin. Thcso; 
changes have been shown to be present at the adenoma and carcinoma stage in F AP and 
sporadic lesions. To the investigator's knowledge the expression of these proteins has not 
been evaluated in HNPCC adenomas. 
This study found focal E-cadherin loss in 30% of HNPCC adenomas. This is the same 
percentage as that found by Valizadeh et aI. (30%) and similar to the findings of 
Gagliardi et aI. (25%) in unselected colon tumourS.25,31 46% ofHNPCC cancers showed 
diffuse loss of staining. This is the same as the findings of Dorudi et aI. (46%) and very 
similar to the results of Gagliardi et aI. (44%) in unselected cases. 25,29,31 The loss of E-
cadherin showed a significant correlation with a shift ofbeta-catenin from the membrane 
to the nucleus. The hypothesis regarding E-cadherin was thus supported. 
Increased expression of nuclear cyctin DI was found focally in 30% of the HNPCC 
adenomas. This is similar to that reported by Arber et aI. (34%).38 69% of HNPCC 
carcinomas in this study showed nuclear cyclin D 1 staining. This is higher than that 
found in the Arber et aI. study (30%). The comparison of the two studies is made difficult 
by the difference in scoring of staining. Arber et aI describe positive staining as nuclear 
staining present in >5% of one microscopic field.38 The magnification is however not 
stated making this statement meaningless. Another study has disagreed with their 
findings and showed positive nuclear staining in all of their sporadic colorectal 
carcinomas.50 A positive correlation was found between nuclear beta-catenin and 
increased cyclin DI staining. The hypothesis regarding cyclin DI was thus supported. 
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C-myc staining was found to be highly heterogeneous in the carcinomas studied. 3/13 
showed increased nuclear staining when compared to the adjacent epithelium. The 
remaining 10 showed equal or decreased staining. Five tumours showed increased 
cytoplasmic staining, including the three with increased nuclear staining. This is in 
apparent conflict with studies perfonned in the late eighties, that showed increased c-myc 
RNA and protein in all colonic cancers using Western blotting, Northern blotting and 
immunohistochemical staining.45-47 This elevated c-myc could however not be shown by 
Wang et al. in their recent study. Using immunohistochemistry and PCR they 
demonstrated that while c-myc m-RNA was increased in 2/3 of tumours, c-myc nuclear 
protein expression as detected by immunohistochemistry, was not increased. They did not 
comment on the presence or absence of cytoplasmic staining. The decreased nuclear 
staining was substantiated by Western blot which also showed an unaltered or decreased 
c-myc level. The Wang et al. study was however small, including only 12 colonic 
cancers. Furthennore five of the twelve were tumours of the right colon, raising the 
possibility that these may represent unsuspected HNPCC or sporadic MSI-H lesions. 50 
Royds et al. also found decreased nuclear staining in carcinomas, but noted an increase in 
cytoplasmic staining. They used electron microscopy to demonstrate that this was 
genuine binding to polyribosomes and not staining artifact. The finding of cytoplasmic c-
myc may explain the increase in c-myc found in studies using Western and Northern 
blotting and not immunohistochemistry. The major function of c-myc is thought to be in 
the nucleus where it is involved in progression through the cell cycle. It is possible that 
cytoplasmic c-myc perfonns an as yet unknown function. 49 
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No relationship was found in this study between beta-catenin and c-myc expression. This 
is in contrast to cell culture studies, using hwnan colon cancer cell lines, which have 
shown that nuclear beta-catenin leads to increased expression of c-myc.41 Wang et al. 
however found no relationship between beta-catenin and c-myc expression. They thus 
hypothesised that nuclear localization of beta-catenin and c-myc expression are not 
linked in-vivo. 50 The cell culture experiments of Kollings et al. showed that gamma-
catenin activation of the TCF transcription factor leads to an increase in c-myc 
expression. This function was independent of beta-catenin, which they found to have no 
effect on c-myc expression.43 Gamma-catenin expression is increased in about 85% of 
sporadic colon cancers.42 
One explanation for the low incidence of c-myc increase in the current study may be due 
to the fact that the tumours are from HNPCC patients and not sporadic cancers. Rothberg 
et al. showed a significant correlation between increased c-myc expression and tumours 
of the left colon, with significantly less c-myc expression in tumours of the right colon 
They thus suggested that increased c-myc is less prominent in HNPCC carcinomas 
compared to F AP and sporadic tumours.98 The studies showing an increase in c-myc in 
all tumours do not specify whether their cases are sporadic or familial, or from the right 
or left colon.45-47 It is, however, likely that most originated from the left as these tumours 
are more common. A possible explanation for this finding of decreased c-myc expression 
in tumours from the right side of the colon, is that the level of APe mutation is thought to 
be lower in tumours from HNPCC patients, with an increased contribution by beta-
catenin mutations. 77 Since gamma-catenin is regulated by APC, the lower incidence of 
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APe mutations may also lead to less gamma-catenin expression, with possible effects on 
the expression of c-myc. 
In the absence of a relationship to beta-catenin staining, a correlation with tumour 
differentiation was sought. No correlation with nuclear staining could be demonstrated, 
but increased cytoplasmic staining was positively correlated with poor differentiation. 
Sikora et al. showed a similar result with increased cytoplasmic staining in poorly 
differentiated tumours.45 
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CHAPTER 4: CONCLUSION 
This study demonstrates that beta-catenin plays as significant a role in HNPCC adenomas 
and carcinomas, as it does in sporadic tumours. Chemopreventative and 
chemotherapeutic strategies targeting beta-catenin, which are currently the focus of much 
attention, are thus appropriate in these individuals. 
4.1 THERAPEUTIC IMPLICATIONS 
The demonstration of the role and importance of beta-catenin!fCF signals has raised the 
possibility of developing cancer therapies based on targeting this pathway. Kim et al. 
demonstrated that the inhibition of the oncogenic form of beta-catenin is sufficient to 
reverse the transformed properties of human cancer cell lines. 99 They thus provided 
evidence that pharmacological inhibition of oncogenic beta-catenin is likely to be an 
effective strategy for reversing the malignant properties of advanced human tumours with 
upregulated beta-catenin. 
Various laboratories have used different methods to target this pathway. Chen et al. 
introduced a cell death gene fadd under the control of wild-type TCFILEF into colon 
cancer cell lines. They were able to selectively target tumour cells that had defects in the 
wntibeta-cateninffCF signal transduction pathway:()() Kwong et al. achieved a similar 
result using gene therapy in nude mice. They introduced a recombinant adenovirus, 
which carries a herpes simplex virus thymidine kinase gene under the control of a beta-
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cateninffCF-response promoter linking to a minimum CMV promoter. A combination of 
the adenovirus and gancyclovir suppressed the growth of colon cancer cells with up 
regulated beta-catenin in the mice. 101 
A simpler approach is the use of anti-inflammatories. Non-steroidal anti-inflammatories 
reduce beta-cateninfTCF transcription. They do this via the inactivation of a phosphatase 
thus leading to an increase in phosporylated beta-catenin and greater beta-catenin 
degradation. 102 
4.2 FUTURE STUDIES 
1) Sporadic MSI-H tumours were not included in this study. It has been suggested that 
the wnt pathway is less involved in these lesions. A study, similar to the current one, 
but focusing on these sporadic cases would be useful. 
2) Evaluation of gamma-catenin expression in HNPCC tumours, and the possible link 
between gamma-catenin expression and c-myc expression. 
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